Document is current
Any future updates will be listed below
-
Authors
Kim, Jin Seok https://orcid.org/0000-0001-8986-8436
Song, Yang
Jen, Wei-Ying
Chim, C. S. https://orcid.org/0000-0003-2427-915X
Lee, Je-Jung https://orcid.org/0000-0002-4635-5697
Yoon, Sung-Soo https://orcid.org/0000-0003-2591-7459
Ng, Soo Chin
Gan, Gin Gin
Handa, Hiroshi https://orcid.org/0000-0003-3753-9862
Lee, Jae Hoon
Kim, Kihyun
Ito, Shigeki
Huang, Jeffrey Shang-Yi
Min, Chang Ki
Ooi Gaik Ming, Melissa https://orcid.org/0000-0002-7392-0655
de Mel, Sanjay https://orcid.org/0000-0002-8881-3537
Soekojo, Cinnie
Li, Xinhua
Awasthi, Neha
Pokharkar, Yogesh
Durie, Brian GM
Chng, Wee-Joo https://orcid.org/0000-0003-2578-8335
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada (They provided the study drug (pomalidomide) and also some funding for conduct of the study)
- License Information
-
More Information
Article History
Received: 1 March 2025
Revised: 15 July 2025
Accepted: 19 August 2025
First Online: 6 October 2025
Competing interests
: The authors declare no relevant conflict of interest. The study drug pomalidomide is provided by BMS who also provided some research funding for the study.
: The study was performed in compliance with the requirements of the local regulatory authorities in Singapore, Hong Kong, Taiwan, South Korea, Malaysia, and Japan, and was conducted in accordance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) regulations. The study was approved by the Domain Specific Review Board (DSRB) in Singapore (DSRB reference 2017/00228) and the respective IRB of participating countries. Written informed consent in accordance with federal, local, and institutional guidelines was obtained from all subjects.
